Company news
Cambium Bio Ltd (ASX:CMB) news
Cambium Bio Ltd news releases on 6ix. Latest, Aug 19, 2020: US Patent for Sygenus
Press releases — page 2
US Patent for Sygenus
August 18, 2020
Regeneus and Kyocera sign Progenza OA deal
August 11, 2020
Progenza OA Kyocera negotiations update
July 27, 2020
Kyocera completes Progenza Due Diligence
May 17, 2020
Appendix 4C Updated
May 5, 2020
Regeneus to be granted new key Progenza patent in U.S.
March 22, 2020
Regeneus receives A$1.6M milestone payment from Kyocera
March 19, 2020
Regeneus signs MOU with Kyocera Corporation
March 1, 2020
Half-Year Results & Business Update
February 28, 2020
Directors provide $4m loan facility
February 28, 2020
AGC Agreement termination paves way for commercial partner
December 19, 2019
CEO Presentation to 2019 Annual General Meeting
November 21, 2019
Chairmans Address to Shareholders
November 21, 2019
Japanese Biotech Fund takes up all Rights Issue Shortfall
November 19, 2019
Regeneus receives A$1.5 million in R&D Tax Incentives
October 15, 2019
Appendix 4E
August 29, 2019
Restructuring results in 50% reduction in operating costs
August 13, 2019
Updated Investor Presentation
August 7, 2019
Offer Booklet
August 1, 2019
Investor Presentation
August 1, 2019
Successful Private Placement
August 1, 2019
Positive results for Progenza in treating neuropathic pain
July 23, 2019
Directors Provide $2.5M Loan to Extend Funding Runway
February 28, 2019
Response to ASX Appendix 4C Query Letter
February 21, 2019
New CEO Appointed to Accelerate Global Growth
January 22, 2019
Chinese patent granted for biomarkers for stem cell therapy
December 2, 2018
Re-Released - Appendix 4C - Quarterly
October 23, 2018
Progenza patent to grant in Europe
October 17, 2018
Regeneus receives R&D tax incentive refund of $2.4m
September 5, 2018
Positive clinical trial results for cancer vaccine
July 30, 2018
US Patent Office to allow key patent for Progenza
July 9, 2018
Update on licensing Progenza in Japan
July 3, 2018
European Medicines Agency grants Progenza ATMP status
February 13, 2018
Japanese Patent Office to grant patent for cancer vaccine
February 11, 2018
Regeneus Announces Successful Results in Acne Study
February 6, 2018
CEO Presentation to 2017 Annual General Meeting
November 2, 2017
Sygenus shows longer lasting effect on pain than morphine
September 25, 2017
Regeneus receives R&D tax incentive refund of $2.6m
August 29, 2017
Appendix 4E Revised
August 22, 2017
US patent allowed for Sygenus for acne
July 9, 2017
RGS to receive milestone payment for successful Phase I
June 20, 2017
Japanese Patent Office to grant key patent for Progenza
May 23, 2017
Positive clinical trial results for Progenza
May 22, 2017
Chinese patent granted on stem cell secretions technology
March 27, 2017
Regeneus receives upfront payment of US$5.5m from AGC
January 22, 2017
Regeneus and AGC collaborate on Progenza in Japan
December 28, 2016
Japan Update
October 16, 2016
Regeneus receives R&D tax incentive refund of $2.7m
September 11, 2016
Appendix 4E and Annual Report 2016
August 23, 2016
European patent to grant on stem cell secretions for acne
August 1, 2016